Vertex Pharmaceuticals: Important Diversification Leads to Big Picture Breakout

I've previously refrained from including Vertex (VRTX) in my portfolio due to its high dependency on the cystic fibrosis (CF) franchise and the looming market saturation. With the FDA's approval expansions for ALYFTREK (from age 6) and TRIKAFTA (from age 2), approximately 95% of CF patients in the U.S. can now be addressed. The progress in diversification is providing new buy signals. The latest impetus comes from the FDA's approval of CASGEVY (CRISPR/Cas9 gene-editing cell therapy)  for patients aged 12 years and older, now extending to children...